Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparing risks of major bleeding and recurrent acute venous thromboembolism (VTE) with apixaban versus warfarin in the treatment of acute venous thromboembolism (VTE)

Trial Profile

Comparing risks of major bleeding and recurrent acute venous thromboembolism (VTE) with apixaban versus warfarin in the treatment of acute venous thromboembolism (VTE)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Warfarin (Primary) ; Anticoagulants
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 May 2019 Results comparing healthcare expenditures between patients receiving outpatient pharmacotherapy with apixaban versus warfarin for VTE in US clinical practice, presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 18 Mar 2019 Results presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 07 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top